Cargando…

Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)

Background: Canine mastocytomas (mast cell tumors) represent a common malignancy among many dog breeds. A typical treatment strategy for canine mastocytomas includes surgery, chemo- and radio-therapy, although in many cases the therapy fails and the disease progression resumes. New treatment approac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilyinskaya, Galina V., Mukhina, Elena V., Soboleva, Alesya V., Matveeva, Olga V., Chumakov, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995045/
https://www.ncbi.nlm.nih.gov/pubmed/29915788
http://dx.doi.org/10.3389/fvets.2018.00116
_version_ 1783330547379994624
author Ilyinskaya, Galina V.
Mukhina, Elena V.
Soboleva, Alesya V.
Matveeva, Olga V.
Chumakov, Peter M.
author_facet Ilyinskaya, Galina V.
Mukhina, Elena V.
Soboleva, Alesya V.
Matveeva, Olga V.
Chumakov, Peter M.
author_sort Ilyinskaya, Galina V.
collection PubMed
description Background: Canine mastocytomas (mast cell tumors) represent a common malignancy among many dog breeds. A typical treatment strategy for canine mastocytomas includes surgery, chemo- and radio-therapy, although in many cases the therapy fails and the disease progression resumes. New treatment approaches are needed. Aims: The goal of this pilot study was to examine safety and efficacy of oncolytic Sendai virus therapy administered to canine patients with cutaneous or subcutaneous mastocytomas. Materials and Methods: Six canine patients, with variable grades and stages of the disease, received virus therapy, either as a monotherapy, or in combination with surgery. The therapy included two or more virus applications administered weekly or biweekly. Each application of Sendai virus (10(7)-10(8.6) EID50) consisted of multiple individual 0.01–0.1 ml injections delivered intratumorally, intradermally around a tumor, and under a tumor bed. Results: The treatment was well tolerated, with minor transitory side effects. Of the six dogs, two did not receive surgery or any other treatment besides the virus injections. The other four animals underwent radical or debulking surgeries, and in three of them the subsequent administration of Sendai virus completely cleared locally recurrent or/and remaining tumor masses. Five dogs demonstrated a complete response to the treatment, the animals remained disease free during the time of observation (2–3 years). One dog responded only partially to the virotherapy; its after-surgical recurrent tumor and some, but not all, metastases were cleared. This dog had the most advanced stage of the disease with multiple enlarged lymph nodes and cutaneous metastases. Conclusion: The results of the pilot study suggest that Sendai virus injections could be safe and efficient for the treatment of dogs affected by mastocytomas.They also suggest the need of further studies for finding optimal schemes and schedules for this kind of therapy.
format Online
Article
Text
id pubmed-5995045
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59950452018-06-18 Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study) Ilyinskaya, Galina V. Mukhina, Elena V. Soboleva, Alesya V. Matveeva, Olga V. Chumakov, Peter M. Front Vet Sci Veterinary Science Background: Canine mastocytomas (mast cell tumors) represent a common malignancy among many dog breeds. A typical treatment strategy for canine mastocytomas includes surgery, chemo- and radio-therapy, although in many cases the therapy fails and the disease progression resumes. New treatment approaches are needed. Aims: The goal of this pilot study was to examine safety and efficacy of oncolytic Sendai virus therapy administered to canine patients with cutaneous or subcutaneous mastocytomas. Materials and Methods: Six canine patients, with variable grades and stages of the disease, received virus therapy, either as a monotherapy, or in combination with surgery. The therapy included two or more virus applications administered weekly or biweekly. Each application of Sendai virus (10(7)-10(8.6) EID50) consisted of multiple individual 0.01–0.1 ml injections delivered intratumorally, intradermally around a tumor, and under a tumor bed. Results: The treatment was well tolerated, with minor transitory side effects. Of the six dogs, two did not receive surgery or any other treatment besides the virus injections. The other four animals underwent radical or debulking surgeries, and in three of them the subsequent administration of Sendai virus completely cleared locally recurrent or/and remaining tumor masses. Five dogs demonstrated a complete response to the treatment, the animals remained disease free during the time of observation (2–3 years). One dog responded only partially to the virotherapy; its after-surgical recurrent tumor and some, but not all, metastases were cleared. This dog had the most advanced stage of the disease with multiple enlarged lymph nodes and cutaneous metastases. Conclusion: The results of the pilot study suggest that Sendai virus injections could be safe and efficient for the treatment of dogs affected by mastocytomas.They also suggest the need of further studies for finding optimal schemes and schedules for this kind of therapy. Frontiers Media S.A. 2018-06-04 /pmc/articles/PMC5995045/ /pubmed/29915788 http://dx.doi.org/10.3389/fvets.2018.00116 Text en Copyright © 2018 Ilyinskaya, Mukhina, Soboleva, Matveeva and Chumakov. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Ilyinskaya, Galina V.
Mukhina, Elena V.
Soboleva, Alesya V.
Matveeva, Olga V.
Chumakov, Peter M.
Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
title Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
title_full Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
title_fullStr Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
title_full_unstemmed Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
title_short Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
title_sort oncolytic sendai virus therapy of canine mast cell tumors (a pilot study)
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995045/
https://www.ncbi.nlm.nih.gov/pubmed/29915788
http://dx.doi.org/10.3389/fvets.2018.00116
work_keys_str_mv AT ilyinskayagalinav oncolyticsendaivirustherapyofcaninemastcelltumorsapilotstudy
AT mukhinaelenav oncolyticsendaivirustherapyofcaninemastcelltumorsapilotstudy
AT sobolevaalesyav oncolyticsendaivirustherapyofcaninemastcelltumorsapilotstudy
AT matveevaolgav oncolyticsendaivirustherapyofcaninemastcelltumorsapilotstudy
AT chumakovpeterm oncolyticsendaivirustherapyofcaninemastcelltumorsapilotstudy